



479
YC
8-13-02

COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd RIEDL et al.

Serial No.: 09/777,920

Filed: February 7, 2001

Title: INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR
PYRIDYL UREAS

RECEIVED

Examiner: Desai, Rita J.

JUL 26 2002

Group Art Unit: 1625

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the office action dated January 15, 2002, please consider the remarks

below:

REMARKS

Election/Restriction

Applicants affirm their election of Group I and maintain their traverse of the restriction requirement. It has not been shown that examination of the full scope of the claims would be an undue burden. The compounds of formula I have the moiety "B" defined as substituted and unsubstituted quinoline, isoquinoline or pyridinyl groups. Claims to such compounds clearly have a common nucleus. It has not been shown how the substituents on A and B, such as R_x, R_f and R_z would require separate searches. The substituents on B do not change its identity as a substituted quinoline, isoquinoline or pyridinyl group. Therefore, Applicants maintain that examination of the full scope of claims 1-33, with all of the variations for R_x, R_z and R_f would not be an undue burden.

Claim Objections

The objection to claims 31-33 as containing figures is not understood. These claims

479
YC
8-13-02